ClinicalTrials.gg
Active, not recruitingNCT04060056WeBirthUpdated Sep 25, 2026

Westlake Precision Birth Cohort

An interventional study of Standardized breakfast and Standardized snack in Diabetes, Gestational, Pregnancy in Diabetics and Intrauterine Hyperglycemia, sponsored by Westlake University. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Westlake University · Not applicable, Interventional, and Prevention

How we know

Updated Sep 25, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,001
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Diabetes, Gestational with a site in China — 19 open to participants now, 23 under way, none of them phase 3. Diabetes, Gestational · China.

Enrollment
2nd of 39
2,001 · median 291
Started
2019
with 13 others
No phase
36 of 68
7 open now
Primary completion
2024-04
later than 4 of 22 live
Registered
25th of 68
by date
Lead sponsor
3 of 68
Westlake University

Among the 68 studies in Diabetes, Gestational with a site in China, this one is the 2nd largest by enrollment of the 39 interventional ones that give a count, is one of 14 that started in 2019, is one of 36 with no phase, reaches primary completion later than 4 of the 22 other live ones, and was the 25th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

19 of the 68 studies in Diabetes, Gestational with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Diabetes, Gestational with a site in China, or all of them as a file.
02

Study summary

The Westlake Precision Birth Cohort (WeBirth) is a prospective cohort study among women with hyperglycemia during pregnancy and their offspring living in Hangzhou, China. The primary aim of this cohort is to characterize the continuous blood glucose response to dietary intake and physical activity among pregnant women with gestational diabetes mellitus (GDM) over 2 weeks, and to facilitate the development of personalized nutritional/lifestyle recommendation among these patients. Another aim of WeBirth is to investigate the association of dietary intake and physical activity together with continuous glucose change during pregnancy on the adverse birth outcomes including preterm birth, macrosomia and large-for-gestational-age birth. The secondary aim is to investigate the prospective associations of diet, physical activity and continuous glucose change over 2 weeks among the participants with long-term metabolic health of these women and their offspring.

Read the detailed description

In China, an alarming increase in the prevalence of GDM has been observed in the past decade. GDM is of concern because it is associated with several maternal and fetal medical disorders. Lifestyle changes such as diet and physical activity modifications are key for the prevention and treatment of GDM. However, the associations between dietary intake and physical activity and health outcomes for GDM women and their children remain unclear due to subjective measurements of diet and physical activity. Recently, the development of objective measurements such as food image identification and wearable activity trackers give an opportunity to gain more precise insight into these associations. In addition, for the same food and physical activity exposures, GDM women may have different blood glucose responses, but the nature of variation is currently poorly characterized. Therefore, the present WeBirth design incorporates three unique components, 1) objective measurement of physical activity during pregnancy using accelerometer; 2) measurement of dietary intake using both the Food Frequency Questionnaire and dietary records; 3) measurement of blood glucose levels over 2 weeks using continuous glucose monitors, with three standardized test meals during the 2 weeks. We will then follow up these women participants during and after this pregnancy, and also follow up their offspring.

03

Conditions studied

  • Diabetes, Gestational
  • Pregnancy in Diabetics
  • Intrauterine Hyperglycemia

Keywords

  • Precision Nutrition
  • Host and Microbiome
  • Birth Outcomes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 years or older
  • Women with GDM at 24-28 weeks of gestation
  • Women intended to deliver at Hangzhou Women's Hospital
  • Women intended to remain in Hangzhou with their child for ≥4 years

Exclusion criteria

Exclusion Criteria:

● Women with cancer and other serious medical disorders

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
2,001 participants (actual)

Study arms

  • Other
    Standardized breakfast

    Egg (50g), whole-wheat bread (35g), celery (30g), and dried bean curd (10g)

    Other: Standardized breakfast

  • Other
    Standardized snack

    Tomato (50g) and skim milk (200g)

    Other: Standardized snack

  • Other
    Standardized lunch

    Rice (40g), oats (40g), shrimp (70g), lettuce (80g), lean pork (30g), carrot (10g), soaked auricularia auricula (20g), broccoli (80g), cucumber (10g), tomato egg drop soup (200g), salt (3g), and oil (8g)

    Other: Standardized lunch

Interventions

  • OtherStandardized breakfast

    Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.

  • OtherStandardized snack

    Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.

  • OtherStandardized lunch

    Participants will be provided with a standardized lunch 2 h after they have the standardized snack.

06

What researchers measure

Primary outcomes

  1. Continuous blood glucose change over 2 weeks

    Glucose levels are assessed by continuous glucose monitoring over 2 weeks.

    Time frame: Two weeks after enrollment

  2. Adverse birth outcomes

    Number of participants with adverse birth outcomes, such as, preterm birth, macrosomia and neonatal hypoglycemia.

    Time frame: 9-12 weeks after enrollment

Secondary outcomes

  1. Body fat of the maternal participants

    Body fat is assessed by the equipment of dual-emission X-ray absorptiometry (DXA) for the mothers.

    Time frame: 6 months and 3 years after delivery

  2. Weight changes of the children during early childhood

    Weight in kilograms

    Time frame: at delivery, age of 6 months, 1 year, 3 years and 6 years

  3. Number of participants developing type 2 diabetes

    Risk of developing type 2 diabetes after the delivery of the women with gestational diabetes.

    Time frame: 6 years and 10 years after delivery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Apr 2024, 56 months.

Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's 56 months is above that.

Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Nov 2025 → Apr 2024 and completion Aug 2029 → Aug 2035.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2019
First posted
Aug 16, 2019
StartActual
Aug 30, 2019
Primary completionActual
Apr 30, 2024was Nov 2025
CompletionEst.
Aug 31, 2035was Aug 2029
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 30, 2025→Apr 30, 2024 (actual)
Sep 25, 2026
Study completion
Aug 31, 2029→Aug 31, 2035
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Primary completion Nov 30, 2025→Apr 30, 2024 (now actual)
    Study completion Aug 31, 2029→Aug 31, 2035
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04060056
Lead sponsor
Westlake University
Collaborators
Hangzhou Maternal and Child Health Hospital
Responsible party
Sponsor
First posted
Aug 16, 2019
Start date
Aug 30, 2019
Primary completion
Apr 30, 2024
Completion
Aug 31, 2035 (estimated)
Last update
Sep 25, 2026

Study contacts

Ju-Sheng Zheng, PhD
principal investigator · Westlake University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion